AKTXAkari Therapeutics, Plc

7.850USD-0.63%Mkt Cap: 15.28M $P/E: Infinity

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that lead…

Key Statistics

Company
Market Cap15.28M $
Enterprise Value8.17M $
Revenue (TTM)
Gross Profit
Net Income (TTM)-17.30M $
Revenue/Share
Last Price7.850 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS00972G1085
Valuation
P/E (Trailing)Infinity
P/E (Forward)-0.56
PEG
EV/EBITDA
EV/Revenue
P/S
P/B0.73
EPS (TTM)0.00
EPS (Forward)-14.00
52W Range
7.04176% of range8.100
52W High8.100 USD
52W Low7.041 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-61.06%
ROA-36.12%
Growth
Revenue Growth
Earnings Growth
Cash Flow & Leverage
Operating CF-10.57M $
CapEx (TTM)
FCF Margin
FCF Yield-56.70%
Net Debt-7.00M $
Net Debt/EBITDA
Balance Sheet
Debt/Equity0.03
Current Ratio0.60
Quick Ratio0.55
Book Value/Sh10.62 USD
Cash/Share3.952 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay Date
Splits
Last Split1:40
Split DateMar 31, 2026
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)28.50 USD
Upside (mean)+263.1%
Target Range27.00 USD30.00 USD
$27.00+263.1% to mean$30.00
# Analysts2
Ownership
Shares Out.1.95M
Float1.20M
Insiders15.46%
Institutions7.73%
Short Interest
Short Ratio0.4d
Short % Float2.97%
Short % Out.1.56%
Shares Short27.30K
Short (prev mo.)18.00K
Technical
SMA 5010.20 (-23.1%)
SMA 20010.74 (-26.9%)
Beta
S&P 52W Chg18.16%
Avg Vol (30d)59.91K
Avg Vol (10d)64.77K
Technical Indicators
RSI (14)44.1
MACD-0.6601
MACD Signal-0.8436
MACD Hist.+0.1836
BB Upper8.562 USD
BB Middle7.733 USD
BB Lower6.905 USD
BB Width21.43%
ATR (14)0.9455 USD
Vol Ratio (20d)0.24x